Management


Daniel J. O'Connell 

PRESIDENT & CEO

Dan O’Connell has over 15 years of early-stage venture creation and investment experience, with a particular emphasis on start-up life sciences companies and their scientific and entrepreneurial founders.  Since December 2014, he has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc.

Mr. O’Connell is a founding member and managing partner of NeuroVentures, a specialty venture capital firm he helped establish in 2001 to invest in emerging biopharmaceutical and medical technology companies seeking to develop novel treatments for diseases and disorders of the Central Nervous System. 

In 2010, Mr. O’Connell co-founded and until August 2014, served as CEO of Functional NeuroModulation Ltd., a medical technology company developing deep brain stimulation therapies for Alzheimer’s disease and other conditions of impaired memory.  Mr. O’Connell is also a co-founder and CEO of Direct Spinal Therapeutics, Inc., a company developing novel spinal cord modulation technology licensed from the University of Iowa and University of Virginia.

Mr. O’Connell serves as an advisor to The Epilepsy Therapy Project, the Alzheimer’s Drug Discovery Foundation and the Brown Institute for Brain Science.  He holds a B.A. from Brown University and M.B.A. from the University of Virginia.

William F. Goure, Ph.D. 

Chief Operating Officer

Since August 2006, Dr. Goure has been Chief Operating Officer of Acumen Pharmaceuticals.  From May 2008 to December 2011, Dr. Goure was also President and interim Chief Executive Officer for Acumen, and from March 2004 to August 2006, Dr. Goure was Vice-President for Business Development and Director of Medicinal Chemistry for Acumen.

Dr. Goure has consulted for the Bill and Melinda Gates Foundation and the Foundation for the National Institute of Health on the Target Malaria and Eliminate Dengue programs and has been a business development Advisor to VM Discovery and VM Pharma of Fremont California.

Dr. Goure has over 30 years of domestic and international experience in the discovery, development, registration, and commercialization of chemical and biotechnology products.

Prior to joining Acumen, Dr. Goure was Vice-President for Commercial Development for Mendel Biotechnology, a San Francisco company focused on plant genomics.  At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated over $29 million dollars of near term revenues. 

Prior to joining Mendel, Dr. Goure worked for Monsanto Company for 17 years where he was a key member of teams that developed and commercialized Roundup Ready® soybeans, canola, cotton, corn, and sugar beets.  Dr. Goure was a member of the team that established Monsanto’s quality traits program that led to the Renessen joint venture with Cargil, and was responsible for establishing commercial launch teams in Eastern Europe, South Africa, and Southern Latin America. 

Dr. Goure has a B.S. degree in Chemistry from Fort Lewis College, Durango Colorado, and a Ph.D. degree in organic chemistry from Iowa State University.  Prior to joining Monsanto, Dr. Goure was a Post-Doctoral Fellow at Colorado State University.


Board of Directors


Franz F. Hefti, Ph.D. 

Acumen Board of Directors
 

Dr. Franz F. Hefti is an expert in drug discovery and development for Alzheimer’s disease and other nervous system diseases. Prior joining Acumen, he was Chief Scientific Officer at Avid Radiopharmaceuticals Inc., a company that developed an imaging diagnostic for Alzheimer’s disease and acquired by Lilly in 2010, and Executive Vice President of Drug Development at Rinat Neuroscience, a company with antibody programs for Alzheimer’s disease and pain indications and acquired by Pfizer in 2006.

Before the years in small biotech companies, Dr. Hefti held senior management positions at Merck & Co. and Genentech, and he was Professor at the University of Southern California and Associate Professor at the University of Miami, where he carried out seminal research on therapeutic applications of neurotrophic factors.

He published over 250 papers on neurotrophic factors and topics in neuropharmacology, as well as a textbook “Drug Discovery for Nervous System Diseases”. Dr. Hefti received his PhD from the University of Zurich and did his postdoctoral research at the Massachusetts Institute of Technology and the Max Planck Institute in Munich.


Jeffrey Ives, Ph.D 

Principal,
NeuroPharma Advisors, LLC  

Dr. Ives has over 30 years of senior scientific leadership experience in the development of novel therapeutics, with an emphasis on drugs for central nervous system diseases. Dr. Ives is a Principal for NeuroPharma Advisors, LLC, a Boston area advisory group dedicated to assisting companies developing therapeutics for central nervous system diseases. Prior to NeuroPharma Advisors, Dr. Ives was CEO of Satori Pharmaceuticals, which was a leading company in the development of gamma-secretase modulators for the treatment of Alzheimer's disease. Before Satori, Dr. Ives held numerous senior management and scientific leadership positions at Pfizer including Senior Vice President of Portfolio Research, Senior Vice President of Phamacokinetics, Dynamics and Metabolism, Vice President of Central Nervous System Research, and Executive Director of Central Nervous System Medicinal Chemistry. Dr. Ives earned his Ph.D. in Chemistry from Yale University and his Bachelor's degree in Chemistry from Colgate University.

Grant A. Krafft, Ph.D.

Chairman, Co-Founder,
and Chief Scienctifc Advisor
 

Dr. Grant Krafft is a co-founder of Acumen and currently serves as Chief Scientific Adviser and Chairman of the Board of Directors.Dr. Krafft was formally Acumen’s Chief Scientific Officer.

Prior to Acumen, Dr. Krafft was Research Professor of Molecular Pharmacology and Biological Chemistry at Northwestern University Medical School, where he and his colleagues discovered Amyloid-beta Derived Dementing Ligands (ADDLs).

Dr. Krafft also served as Director of Research Development for the ENH Research Institute, a Northwestern University Medical School affiliate. Previously, Dr. Krafft was Chief Technical Officer of Tibotec-Virco, a HIV therapeutics and pharmacogenomics company, and a Volwiler Research Fellow at Abbott Laboratories in its Diagnostics and Pharmaceutical Products Divisions.

Dr. Krafft holds a B.S. in Chemistry from Valparaiso University, and a Ph.D. in Organic Chemistry from the University of Illinois, Urbana-Champaign, and was a NIH post-doctoral fellow at the University of Wisconsin, Madison.

Dr. Krafft is an author on more than 75 scientific papers and a co-inventor on more than 20 issued and pending patents.


Mark Lampert 

Founder of BVF Partners L.P. 

Mark Lampert is the founder of BVF Partners L.P., a San Francisco-based, private investment firm established in 1993. Mr. Lampert has engaged in ventures relating to the biotechnology industry since 1984. Most recently, Mr. Lampert was a Vice President at the investment banking firm Oppenheimer & Co. in New York , where he created novel biotechnology investment vehicles. Prior to joining Oppenheimer & Co., he founded Biotechnology Royalty Corp., which pooled biotechnology patent royalties owned by universities. From 1987 to 1990, Mr. Lampert headed business development for Cambridge NeuroScience, a public biotechnology company. From 1984 to 1986, Mr. Lampert served as Assistant to the President of the NutraSweet Company, a subsidiary of G.D. Searle & Co.. He started his career at the Boston Consulting Group. Mr. Lampert is a Director of Accumen, Inc., Biotica Technology, Ltd, CFD Therapeutics, and Mendel Biotechnology. He holds an AB Degree in chemistry from Harvard College and an MBA Degree from Harvard Business School.

Daniel O'Connell

president & CEO

See Management